Skip to content
★ Sign in to follow
Insider activity · 24 months0 buys2 salesCumulative net flow
Total declarations
26
Company
1
▲ Purchases (17 ops.)
€12k
▼ Sales (8 ops.)
€26k

Latest filing published 31 Dec 2024 for Ajanta Pharma Limited, €3,360.

Filing timeline

BuySale
J K Tripathi

J K Tripathi: trading record in brief

J K Tripathi is a declared insider of Ajanta Pharma Limited, with filings sourced from SEBI (PIT + SAST). In total, 26 filings cover trades dated from 3 November 2023 to 30 December 2024.

Market trades split into 17 purchases (€12k) and 8 sales (€26k). The net balance comes to €14k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. Since January 2024: no purchases and 8 sales on the market.

Half of the purchases are above €536 and half below. Across 17 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 31 December 2024, the filings show an open-market sale worth €3,360 in Ajanta Pharma Limited. The most recent open-market purchase was published on 19 December 2023, 1,055 days ago. Between a trade and the moment it shows up on SEBI (PIT + SAST), the median delay is 38 days. Until a filing is published, the market cannot know about the trade. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.

Companies and markets linked to J K Tripathi

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations26 total
  • ▼
    ExecutivesAjanta Pharma Limited
    300,000 INR3SEBI
    100 shares@ ₹3,000.008.9% of flowEquity SharesSEBI:81aaeec7dc43066be3e1e9f9ab61c9b6f3488d33
  • ▼
    ExecutivesAjanta Pharma Limited
    158,100 INR2SEBI
    51 shares@ ₹3,100.004.5% of flowEquity SharesSEBI:e850b263b0dd81b8e4f70577e477cf6e5d5372fe
  • ▼
    ExecutivesAjanta Pharma Limited
    295,000 INR3SEBI
    100 shares@ ₹2,950.008.8% of flowEquity SharesSEBI:63707ea004b3312b57ff88d5dab7715d4df49aee
  • ▼
    ExecutivesAjanta Pharma Limited
    149,940 INR2SEBI
    49 shares@ ₹3,060.004.3% of flowEquity SharesSEBI:a66349f94b664e7d90294b63148de2daadf02e93
  • ▼
    ExecutivesAjanta Pharma Limited
    289,500 INR3SEBI
    100 shares@ ₹2,895.008.6% of flowEquity SharesSEBI:8b3dfe0f8172ec65bf734b1c670522b5e8ac5e3a
  • ▼
    ExecutivesAjanta Pharma Limited
    561,706 INR4SEBI
    200 shares@ ₹2,808.5316.1% of flowEquity SharesSEBI:0531eeee2c1db1c00ff80caa97ece38e38c2e597
  • ▲
    ExecutivesAjanta Pharma Limited
    1,000 INR2SEBI
    500 shares@ ₹2.000.0% of flowEquity SharesSEBI:5cbe99ce6cbf67e25ee89b99d9323502a0a1814a
    Canonical exit: 5 Nov 2024 (T+90)
  • ▼
    ExecutivesAjanta Pharma Limited
    299,103 INR3SEBI
    100 shares@ ₹2,991.038.4% of flowEquity SharesSEBI:c575c82d88eef26ee0b5df9f62a647a1532482ea
  • ▼
    ExecutivesAjanta Pharma Limited
    320,000 INR3SEBI
    100 shares@ ₹3,200.009.1% of flowEquity SharesSEBI:fe16aa19b56694fbc2cab3ec627b4c1f21fbbc53
  • ▲
    ExecutivesAjanta Pharma Limited
    49,319 INR2SEBI
    27 shares@ ₹1,826.62961.5% of flowEquity SharesSEBI:10ec489a3e1d2bbfa04ce4ed41c677b6ff73d7d8
    Canonical exit: 4 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    45,141 INR2SEBI
    25 shares@ ₹1,805.641.3% of flowEquity SharesSEBI:5434ea2c67cb8276e7c62f7a534c5d0329b9afd7
    Canonical exit: 6 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    55,539 INR2SEBI
    30 shares@ ₹1,851.301.6% of flowEquity SharesSEBI:f83cb80f20a7d9b481455e746dfeb1eb6f34726f
    Canonical exit: 11 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    93,750 INR2SEBI
    50 shares@ ₹1,875.002.8% of flowEquity SharesSEBI:01e0181944a1274c62a7f22b58eeacaf945baedc
    Canonical exit: 11 Mar 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    9,380 INR2SEBI
    5 shares@ ₹1,876.000.3% of flowEquity SharesSEBI:870c9707fc597424d254da399abe84d9a93075b7
    Canonical exit: 8 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    38,721 INR2SEBI
    20 shares@ ₹1,936.051.1% of flowEquity SharesSEBI:a4a0f360a5307fe1a7926b3d9c58d291822e69aa
    Canonical exit: 14 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    94,545 INR2SEBI
    50 shares@ ₹1,890.902.8% of flowEquity SharesSEBI:f64b45c9faaf988880c9b0082a851f5fec60c123
    Canonical exit: 10 Mar 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    90,433 INR2SEBI
    50 shares@ ₹1,808.662.7% of flowEquity SharesSEBI:7e46e9d13627a770fd480c297e18cf1170ea5b0f
    Canonical exit: 7 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    227,881 INR3SEBI
    125 shares@ ₹1,823.0486.8% of flowEquity SharesSEBI:2c10ba041b622d64c1aeaff3e9b5e242bde95c9c
    Canonical exit: 5 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    48,778 INR2SEBI
    25 shares@ ₹1,951.121.4% of flowEquity SharesSEBI:a900a8c7d2953e370cb21cd1fe81e9997537af00
    Canonical exit: 21 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    94,017 INR2SEBI
    50 shares@ ₹1,880.342.7% of flowEquity SharesSEBI:d9a016f2af9a462e070e215924531a1ce63bf7c1
    Canonical exit: 14 Mar 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    9,400 INR2SEBI
    5 shares@ ₹1,880.000.3% of flowEquity SharesSEBI:3db68dd684aaf9aaf55be27fe6667d8ec0bc2c2e
    Canonical exit: 8 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    128,347 INR2SEBI
    70 shares@ ₹1,833.52863.8% of flowEquity SharesSEBI:e500d0d25576c8a3f2742aaacd1c84f94bb7e6bf
    Canonical exit: 1 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    9,395 INR2SEBI
    5 shares@ ₹1,879.000.3% of flowEquity SharesSEBI:f5cd31d00e14f891f5768428cee4b3eb4cca546f
    Canonical exit: 8 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    46,625 INR2SEBI
    25 shares@ ₹1,865.001.4% of flowEquity SharesSEBI:e5ad93820d766e715beb4aa1f44fe24b12802ff9
    Canonical exit: 8 Feb 2024 (T+90)
  • ▲
    ExecutivesAjanta Pharma Limited
    9,415 INR2SEBI
    5 shares@ ₹1,883.000.3% of flowEquity SharesSEBI:f8db66d25c62f53392664f441a6983a177462354
    Canonical exit: 8 Feb 2024 (T+90)

25 of 26 declarations